Market Closed -
OTC Markets
12:46:41 2024-06-20 EDT
|
5-day change
|
1st Jan Change
|
0.000001
USD
|
0.00%
|
|
0.00%
|
0.00%
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Capitalization
1 |
116.9
|
32.89
|
24.84
|
54.13
|
125
|
66.64
|
Enterprise Value (EV)
1 |
70.51
|
34.93
|
13.31
|
33.92
|
69.06
|
46.67
|
P/E ratio
|
-2.35
x
|
-0.59
x
|
-0.85
x
|
-1.1
x
|
-2.18
x
|
-2.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
498
x
|
-
|
-
|
-
|
91.9
x
|
40.6
x
|
EV / Revenue
|
300
x
|
-
|
-
|
-
|
50.8
x
|
28.4
x
|
EV / EBITDA
|
-1.47
x
|
-0.68
x
|
-0.34
x
|
-0.89
x
|
-1.49
x
|
-0.89
x
|
EV / FCF
|
-2.55
x
|
-1.28
x
|
-0.51
x
|
-1.38
x
|
-2.61
x
|
-1.45
x
|
FCF Yield
|
-39.2%
|
-78.4%
|
-195%
|
-72.3%
|
-38.3%
|
-68.7%
|
Price to Book
|
2.57
x
|
-5.5
x
|
3.75
x
|
2.33
x
|
14.3
x
|
2.49
x
|
Nbr of stocks (in thousands)
|
3,547
|
3,545
|
10,828
|
26,150
|
51,635
|
57,445
|
Reference price
2 |
32.96
|
9.280
|
2.294
|
2.070
|
2.420
|
1.160
|
Announcement Date
|
2/17/17
|
2/16/18
|
2/28/19
|
2/13/20
|
2/22/21
|
3/18/22
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Net sales
1 |
0.235
|
-
|
-
|
-
|
1.359
|
1.641
|
EBITDA
1 |
-48.12
|
-51.42
|
-38.83
|
-38.29
|
-46.45
|
-52.34
|
EBIT
1 |
-49.84
|
-52.64
|
-39.52
|
-38.99
|
-46.99
|
-53.19
|
Operating Margin
|
-21,207.23%
|
-
|
-
|
-
|
-3,457.62%
|
-3,241.5%
|
Earnings before Tax (EBT)
1 |
-49.57
|
-56.71
|
-27.81
|
-38.95
|
-43.71
|
-33.2
|
Net income
1 |
-49.57
|
-56.71
|
-27.81
|
-38.95
|
-43.71
|
-33.2
|
Net margin
|
-21,094.89%
|
-
|
-
|
-
|
-3,216.63%
|
-2,022.91%
|
EPS
2 |
-14.01
|
-15.86
|
-2.695
|
-1.890
|
-1.112
|
-0.4841
|
Free Cash Flow
1 |
-27.62
|
-27.37
|
-25.94
|
-24.53
|
-26.42
|
-32.08
|
FCF margin
|
-11,752.93%
|
-
|
-
|
-
|
-1,944.42%
|
-1,954.98%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/17/17
|
2/16/18
|
2/28/19
|
2/13/20
|
2/22/21
|
3/18/22
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Net Debt
1 |
-
|
2.04
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
46.4
|
-
|
11.5
|
20.2
|
55.9
|
20
|
Leverage (Debt/EBITDA)
|
-
|
-0.0396
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-27.6
|
-27.4
|
-25.9
|
-24.5
|
-26.4
|
-32.1
|
ROE (net income / shareholders' equity)
|
-73.3%
|
-287%
|
-4,329%
|
-241%
|
-257%
|
-184%
|
ROA (Net income/ Total Assets)
|
-34.2%
|
-75.3%
|
-102%
|
-58.2%
|
-38.9%
|
-43%
|
Assets
1 |
144.9
|
75.32
|
27.36
|
66.91
|
112.5
|
77.11
|
Book Value Per Share
2 |
12.80
|
-1.690
|
0.6100
|
0.8900
|
0.1700
|
0.4700
|
Cash Flow per Share
2 |
7.710
|
3.420
|
2.430
|
1.460
|
1.500
|
0.6400
|
Capex
1 |
2.54
|
1.18
|
0.24
|
1.14
|
2.59
|
3.29
|
Capex / Sales
|
1,080%
|
-
|
-
|
-
|
190.21%
|
200.37%
|
Announcement Date
|
2/17/17
|
2/16/18
|
2/28/19
|
2/13/20
|
2/22/21
|
3/18/22
|
|
1st Jan change
|
Capi.
|
---|
| 0.00% | 58 | | +19.41% | 45.51B | | +38.65% | 39.36B | | -8.62% | 38.52B | | +26.95% | 30.74B | | -13.50% | 26.03B | | +10.74% | 25.92B | | +44.87% | 14.13B | | +34.36% | 12.73B | | -7.14% | 11.29B |
Other Biotechnology & Medical Research
|